537 related articles for article (PubMed ID: 20109508)
1. The effect of surface functionalization of PLGA nanoparticles by heparin- or chitosan-conjugated Pluronic on tumor targeting.
Chung YI; Kim JC; Kim YH; Tae G; Lee SY; Kim K; Kwon IC
J Control Release; 2010 May; 143(3):374-82. PubMed ID: 20109508
[TBL] [Abstract][Full Text] [Related]
2. In-vivo tumor targeting of pluronic-based nano-carriers.
Kim JY; Choi WI; Kim YH; Tae G; Lee SY; Kim K; Kwon IC
J Control Release; 2010 Oct; 147(1):109-17. PubMed ID: 20600404
[TBL] [Abstract][Full Text] [Related]
3. Enhanced electrostatic interaction between chitosan-modified PLGA nanoparticle and tumor.
Yang R; Shim WS; Cui FD; Cheng G; Han X; Jin QR; Kim DD; Chung SJ; Shim CK
Int J Pharm; 2009 Apr; 371(1-2):142-7. PubMed ID: 19118614
[TBL] [Abstract][Full Text] [Related]
4. Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain.
Wang ZH; Wang ZY; Sun CS; Wang CY; Jiang TY; Wang SL
Biomaterials; 2010 Feb; 31(5):908-15. PubMed ID: 19853292
[TBL] [Abstract][Full Text] [Related]
5. Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides.
Nafee N; Taetz S; Schneider M; Schaefer UF; Lehr CM
Nanomedicine; 2007 Sep; 3(3):173-83. PubMed ID: 17692575
[TBL] [Abstract][Full Text] [Related]
6. Chitosan-modified poly(D,L-lactide-co-glycolide) nanospheres for plasmid DNA delivery and HBV gene-silencing.
Zeng P; Xu Y; Zeng C; Ren H; Peng M
Int J Pharm; 2011 Aug; 415(1-2):259-66. PubMed ID: 21645597
[TBL] [Abstract][Full Text] [Related]
7. The intracellular uptake ability of chitosan-coated Poly (D,L-lactide-co-glycolide) nanoparticles.
Kim BS; Kim CS; Lee KM
Arch Pharm Res; 2008 Aug; 31(8):1050-4. PubMed ID: 18787796
[TBL] [Abstract][Full Text] [Related]
8. Effect of polymer molecular weight on the tumor targeting characteristics of self-assembled glycol chitosan nanoparticles.
Park K; Kim JH; Nam YS; Lee S; Nam HY; Kim K; Park JH; Kim IS; Choi K; Kim SY; Kwon IC
J Control Release; 2007 Oct; 122(3):305-14. PubMed ID: 17643545
[TBL] [Abstract][Full Text] [Related]
9. Effect of preparative variables on small interfering RNA loaded Poly(D,L-lactide-co-glycolide)-chitosan submicron particles prepared by emulsification diffusion method.
Katas H; Chen S; Osamuyimen AA; Cevher E; Oya Alpar H
J Microencapsul; 2008 Dec; 25(8):541-8. PubMed ID: 18465303
[TBL] [Abstract][Full Text] [Related]
10. Photochemical internalization for pDNA transfection: evaluation of poly(d,l-lactide-co-glycolide) and poly(ethylenimine) nanoparticles.
Gargouri M; Sapin A; Arıca-Yegin B; Merlin JL; Becuwe P; Maincent P
Int J Pharm; 2011 Jan; 403(1-2):276-84. PubMed ID: 21044878
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of the targeting capabilities of the Paclitaxel-loaded pluronic nanoparticles with a glycol chitosan/heparin composite.
Yuk SH; Oh KS; Cho SH; Kim SY; Oh S; Lee JH; Kim K; Kwon IC
Mol Pharm; 2012 Feb; 9(2):230-6. PubMed ID: 22149139
[TBL] [Abstract][Full Text] [Related]
12. Preparation and characterization of cationic chitosan-modified poly(D,L-lactide-co-glycolide) copolymer nanospheres as DNA carriers.
Guan XP; Quan DP; Liao KR; Tao Wang ; Peng Xiang ; Mai KC
J Biomater Appl; 2008 Jan; 22(4):353-71. PubMed ID: 17494965
[TBL] [Abstract][Full Text] [Related]
13. A facile method to prepare heparin-functionalized nanoparticles for controlled release of growth factors.
Chung YI; Tae G; Hong Yuk S
Biomaterials; 2006 Apr; 27(12):2621-6. PubMed ID: 16360204
[TBL] [Abstract][Full Text] [Related]
14. Improved cellular uptake of chitosan-modified PLGA nanospheres by A549 cells.
Tahara K; Sakai T; Yamamoto H; Takeuchi H; Hirashima N; Kawashima Y
Int J Pharm; 2009 Dec; 382(1-2):198-204. PubMed ID: 19646519
[TBL] [Abstract][Full Text] [Related]
15. Accelerating thrombolysis with chitosan-coated plasminogen activators encapsulated in poly-(lactide-co-glycolide) (PLGA) nanoparticles.
Chung TW; Wang SS; Tsai WJ
Biomaterials; 2008 Jan; 29(2):228-37. PubMed ID: 17953984
[TBL] [Abstract][Full Text] [Related]
16. Enhanced cellular association of paclitaxel delivered in chitosan-PLGA particles.
Chakravarthi SS; Robinson DH
Int J Pharm; 2011 May; 409(1-2):111-20. PubMed ID: 21356285
[TBL] [Abstract][Full Text] [Related]
17. Colloidal stability of pluronic F68-coated PLGA nanoparticles: a variety of stabilisation mechanisms.
Santander-Ortega MJ; Jódar-Reyes AB; Csaba N; Bastos-González D; Ortega-Vinuesa JL
J Colloid Interface Sci; 2006 Oct; 302(2):522-9. PubMed ID: 16887138
[TBL] [Abstract][Full Text] [Related]
18. Long circulating chitosan/PEG blended PLGA nanoparticle for tumor drug delivery.
Parveen S; Sahoo SK
Eur J Pharmacol; 2011 Nov; 670(2-3):372-83. PubMed ID: 21951969
[TBL] [Abstract][Full Text] [Related]
19. Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin.
Yadav AK; Mishra P; Mishra AK; Mishra P; Jain S; Agrawal GP
Nanomedicine; 2007 Dec; 3(4):246-57. PubMed ID: 18068091
[TBL] [Abstract][Full Text] [Related]
20. Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen.
Slütter B; Bal S; Keijzer C; Mallants R; Hagenaars N; Que I; Kaijzel E; van Eden W; Augustijns P; Löwik C; Bouwstra J; Broere F; Jiskoot W
Vaccine; 2010 Aug; 28(38):6282-91. PubMed ID: 20638455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
